ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 83 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,516,692 | -33.0% | 659,371 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $6,739,742 | +47.5% | 649,927 | +15.0% | 0.00% | 0.0% |
| Q1 2023 | $4,570,388 | -48.9% | 564,943 | -0.4% | 0.00% | -50.0% |
| Q4 2022 | $8,937,637 | +2.6% | 567,469 | +2.5% | 0.00% | 0.0% |
| Q3 2022 | $8,712,000 | +19.2% | 553,484 | +5.7% | 0.00% | 0.0% |
| Q2 2022 | $7,310,000 | -9.8% | 523,679 | +11.4% | 0.00% | +100.0% |
| Q1 2022 | $8,106,000 | +13.8% | 470,166 | -4.0% | 0.00% | 0.0% |
| Q4 2021 | $7,122,000 | -21.1% | 489,796 | -2.4% | 0.00% | -50.0% |
| Q3 2021 | $9,030,000 | +12.6% | 501,633 | +9.9% | 0.00% | +100.0% |
| Q2 2021 | $8,016,000 | +192.4% | 456,436 | +319.5% | 0.00% | 0.0% |
| Q1 2021 | $2,741,000 | +367.7% | 108,795 | +20.0% | 0.00% | – |
| Q4 2020 | $586,000 | +137.2% | 90,687 | -5.3% | 0.00% | – |
| Q3 2020 | $247,000 | +54.4% | 95,782 | -2.9% | 0.00% | – |
| Q2 2020 | $160,000 | -56.8% | 98,606 | -72.2% | 0.00% | – |
| Q1 2020 | $370,000 | -43.1% | 355,127 | +3.3% | 0.00% | – |
| Q4 2019 | $650,000 | +58.9% | 343,852 | -9.1% | 0.00% | – |
| Q3 2019 | $409,000 | -56.7% | 378,294 | -12.3% | 0.00% | – |
| Q2 2019 | $945,000 | -63.8% | 431,462 | -0.9% | 0.00% | -100.0% |
| Q1 2019 | $2,609,000 | -20.7% | 435,581 | -2.1% | 0.00% | 0.0% |
| Q4 2018 | $3,288,000 | -36.1% | 444,942 | +25.6% | 0.00% | 0.0% |
| Q3 2018 | $5,142,000 | -12.7% | 354,151 | +20.0% | 0.00% | 0.0% |
| Q2 2018 | $5,891,000 | +13.7% | 295,033 | -0.2% | 0.00% | 0.0% |
| Q1 2018 | $5,179,000 | -28.0% | 295,571 | +1.4% | 0.00% | -50.0% |
| Q4 2017 | $7,189,000 | -5.0% | 291,523 | -0.6% | 0.00% | 0.0% |
| Q3 2017 | $7,568,000 | +9.1% | 293,259 | +14.7% | 0.00% | 0.0% |
| Q2 2017 | $6,936,000 | +38.1% | 255,738 | +51.8% | 0.00% | +100.0% |
| Q1 2017 | $5,024,000 | +22.0% | 168,488 | +11.1% | 0.00% | 0.0% |
| Q4 2016 | $4,118,000 | +47.3% | 151,721 | +39.0% | 0.00% | 0.0% |
| Q3 2016 | $2,795,000 | +99.8% | 109,138 | +44.2% | 0.00% | – |
| Q2 2016 | $1,399,000 | +28.8% | 75,708 | +32.0% | 0.00% | – |
| Q1 2016 | $1,086,000 | -29.4% | 57,351 | +0.4% | 0.00% | -100.0% |
| Q4 2015 | $1,539,000 | – | 57,142 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |